Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-hydroxymethyl-2'-deoxycytidine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Vaginal, Sublingual, Buccal, Transdermal, Intrathecal, Intratumoral, Intraperitoneal, Parenteral
01
Overview
5-Hydroxymethyl-2'-deoxycytidine (5hmdC) is a modified pyrimidine nucleoside and an oxidation derivative of 5-methyl-2'-deoxycytidine (5-mdC) in DNA. It serves as a key oxidative intermediate in the active DNA demethylation pathway mediated by ten-eleven translocation (TET) family proteins. In biological systems, 5hmdC is deaminated by cytidine deaminase (CDA) into genome-toxic variants of uridine, which are subsequently incorporated into DNA, triggering DNA damage, chromosomal aberrations, replication fork instability (associated with PARP1 on chromatin), and cell death. Due to its narrow cytotoxicity profile, which primarily targets cells overexpressing CDA such as grade IV glioma (U87-MG) and Chronic Myelogenous Leukemia (HAP1) cell lines, 5hmdC is being investigated as a potential chemotherapeutic agent for glioblastoma multiforme and other cancers.
- Other names
- 2'-deoxy-5-(hydroxymethyl)-cytidine5-hydroxymethyl-2'-deoxycytidine5-hydroxymethyl-dC5hmdChmdC
02
Targets
AICDA (AID / AICDA)DNACDA (Cytidine deaminase)
Beyond the preview
Go deeper on 5-hydroxymethyl-2'-deoxycytidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-hydroxymethyl-2'-deoxycytidine.